{"DataElement":{"publicId":"5154374","version":"1","preferredName":"ER Status Other Method Not IHC Performed Result","preferredDefinition":"Text that represents the test result for the patient's estrogen receptor (ER) status, using a test method other than immunohistochemical (IHC) staining.","longName":"5154194v1.0:5154200v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"5154194","version":"1","preferredName":"Estrogen Receptor Status Other Method Negation Immunohistochemistry Staining Method Performed","preferredDefinition":"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a \"late-onset\" form of breast cancer and for an older woman to have an \"early-onset\" variant of the disease._Different than the one(s) previously specified or mentioned._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal._An operation in which a term denies or inverts the meaning of another term or construction._Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen._Executed and carried through to completion.","longName":"5154191v1.0:5154192v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"5154191","version":"1","preferredName":"Estrogen Receptor Status","preferredDefinition":"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a \"late-onset\" form of breast cancer and for an older woman to have an \"early-onset\" variant of the disease.","longName":"C16150","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estrogen Receptor Status","conceptCode":"C16150","definition":"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a \"late-onset\" form of breast cancer and for an older woman to have an \"early-onset\" variant of the disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DC924A2-1C18-CD6C-E050-BB89AD4358FB","latestVersionIndicator":"Yes","beginDate":"2016-03-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-03-11","modifiedBy":"ONEDATA","dateModified":"2016-03-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5154192","version":"1","preferredName":"Other Method Negation Immunohistochemistry Staining Method Performed","preferredDefinition":"Different than the one(s) previously specified or mentioned.:A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.:An operation in which a term denies or inverts the meaning of another term or construction.:Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.:Executed and carried through to completion.","longName":"5154192v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Method","conceptCode":"C71460","definition":"A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Immunohistochemistry Staining Method","conceptCode":"C23020","definition":"Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Performed","conceptCode":"C38000","definition":"Executed and carried through to completion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DC924A2-1C2C-CD6C-E050-BB89AD4358FB","latestVersionIndicator":"Yes","beginDate":"2016-03-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-03-11","modifiedBy":"ONEDATA","dateModified":"2016-03-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"TCGA:The Cancer Genome Atlas","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DC924A2-1C3D-CD6C-E050-BB89AD4358FB","latestVersionIndicator":"Yes","beginDate":"2016-03-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-03-11","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for TCGA BRCA CDF form per request by K.Wildermuth. mc 3/11/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5154200","version":"1","preferredName":"Outcome","preferredDefinition":"The result of an action.","longName":"5154200v1.0","context":"NCIP","contextVersion":"1","type":"Non-enumerated","dataType":"ALPHANUMERIC","minLength":null,"maxLength":"255","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2476191","version":"1","preferredName":"Result","preferredDefinition":"Outcome; a phenomenon that follows and is caused by some previous phenomenon.","longName":"C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"11CE3EF3-93C8-1DC4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-19","modifiedBy":"ONEDATA","dateModified":"2006-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"TCGA:The Cancer Genome Atlas","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DC94499-0923-9472-E050-BB89AD431704","latestVersionIndicator":"Yes","beginDate":"2016-03-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-03-11","modifiedBy":"COOPERM","dateModified":"2016-03-18","changeDescription":"Created for BRCA CDF per request by K.Wildermuth. mc 3/11/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"If a method other than IHC wa","type":"Preferred Question Text","description":"If a method other than IHC was used to determine ER Status, what were the results?","url":null,"context":"NCIP"}],"origin":"CTSP/CDDP: Clinical Trial Sequencing and Cancer Driver Discovery Projects","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DCCE006-3A53-0E37-E050-BB89AD435604","latestVersionIndicator":"Yes","beginDate":"2016-03-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-03-11","modifiedBy":"COOPERM","dateModified":"2016-10-03","changeDescription":"Created for BRCA CDF per request by K.Wildermuth. mc 3/11/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}